1. Home
  2. TNXP vs CNDT Comparison

TNXP vs CNDT Comparison

Compare TNXP & CNDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$13.47

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Logo Conduent Incorporated

CNDT

Conduent Incorporated

HOLD

Current Price

$1.62

Market Cap

234.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
CNDT
Founded
2007
2016
Country
United States
United States
Employees
N/A
51000
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
234.2M
IPO Year
2008
2016

Fundamental Metrics

Financial Performance
Metric
TNXP
CNDT
Price
$13.47
$1.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
425.9K
972.0K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
$3,042,000,000.00
Revenue This Year
$558.11
$2.01
Revenue Next Year
$38.29
$4.06
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$9.40
$1.15
52 Week High
$34.00
$2.98

Technical Indicators

Market Signals
Indicator
TNXP
CNDT
Relative Strength Index (RSI) 59.03 55.67
Support Level $11.98 $1.32
Resistance Level $13.36 $2.05
Average True Range (ATR) 0.79 0.09
MACD 0.09 0.00
Stochastic Oscillator 60.55 57.33

Price Performance

Historical Comparison
TNXP
CNDT

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About CNDT Conduent Incorporated

Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.

Share on Social Networks: